Drug firm Lupin today said it has been granted final approval by the United states Food and Drug Administration (USFDA) for antihistamine Desloratadine tablets, used for treating allergies.
The approval has been given to Lupin Pharmaceuticals, Lupin's wholly owned US subsidiary for Desloratadine tablets in the strength of 5 mg, the company said in a filing to the Bombay Stock Exchange (BSE).
Desloratadine tablets 5 mg are generic version of Clarinex tablets 5 mg of US-based drug major Schering-Plough.
According to IMS Health, clarinex tablets have recorded sales of $229 million for this year, the company added.
The company has filed 132 abbreviated new drug applications for this financial year, of which 45 have been approved by the USFDA.
Shares of Lupin were trading today at Rs 446.15 on the BSE in the afternoon trade, up 0.30 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app